Aar Ess Remedies Private Limited

• Repaglinide I.P: 0.5 mg
• Excipients I.P: q.s

• Form: Tabs
• Pack: 10’
• Type: AA
• Class: Diabeto

• Repaglinide BP: 2 mg
• Excipients: q.s

• Form: Tabs
• Pack: 10’s
• Type: AA
• Class: Diabeto

• Repaglinide BP 1 mg
• Excipients q.s

Specifications

• Form Tabs
• Pack 10''s
• Type AA
• Class Diabeto

• Repaglinide BP: 2mg
• Metformin hydrochloride IP (as sustained release form): 500mg

• Pack Size: 10x10 tablets
• Form: Tabs
• Pack: 10’s
• Type: AA
• Class: Diabeto

• Repaglinide BP: 1mg
• Metformin hydrochloride IP(as sustained release form): 500mg

Specifications:

• Form: Tabs
• Pack: 10’s
• Type: AA
• Class: Diabeto

• Neteglinide USP: 60mg
• Metformin Hydrochloride IP(as sustained release form): 500mg
• Excipients: q.s

• Pack Size: 10x10 tablets
• Form: Tabs
• Pack: 10’s
• Type: Blist
• Class: Diabeto

• Neteglinide USP: 60mg
• Metformin Hydrochloride IP: 500mg
• Voglibose: 0.2mg
• Excipients: q.s

• Pack Size: 10x10 tablets
• Color: Sunset Yellow
• Form: Tabs
• Pack: 10’s
• Type: Blist
• Class: Diabeto

• Neteglinide USP: 60mg
• Excipients: q.s

• Pack Size: 10x10 tablets
• Form: Tabs
• Pack: 10’s
• Type: AA
• Class: Diabeto

Vilhox-50 (Vildagliptin 50mg) Tablets

 Vildagliptin is an oral anti-diabetic agent that enhances pancreatic islet cell responsiveness to glucose. Approximately 22,000 patients and 7000 patient-years of exposure to vildagliptin has shown that the agent is well tolerated and efficacious in improving glycemic control in patients with T2DM. Monotherapy trials have shown that significant HbA1c lowering is accompanied by body weight-neutral and lipid-neutral effects, low risk of edema, and low risk of hypoglycemia. These characteristics make vildagliptin a favorable partner for combination therapy. Studies of vildagliptin as an add-on to metformin have shown significant improvements in glycemic control (comparable to that of thiazolidinedione add-on), with the combination being well tolerated and associated with low risks for hypoglycemia and adverse effects on weight or lipid levels. Good tolerability and clinically relevant improvements in glycemic control have also been observed with vildagliptin as an add-on treatment to sulfonylurea, thiazolidinedione, or insulin treatment or in initial combination treatment with pioglitazone. Improved β-cell function and glycemic control have been shown with vildagliptin in subjects with impaired glucose tolerance and in T2DM patients with mild hyperglycemia, with some evidence in the latter suggesting the potential for modifying disease course

- Vasc Health Risk Manag. 2008 Dec; 4(6): 1349-1360.